EXACT Sciences, headquartered in Madison, Wisconsin, focuses on cancer screening and diagnostics, employing 6,500 people. Its key products include the Cologuard test for colorectal cancer and Oncotype DX tests for breast cancer.
Exact Sciences (EXAS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Exact Sciences's actual EPS was -$4.67, missing the estimate of -$0.31 per share, resulting in a -1392.01% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
